The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
ABPI open letter to the Conservative candidates for Prime Minister
The ABPI calls on the Conservative candidates to prevent the UK slipping behind our global competitors in the race to become a life sciences superpower and to deliver on the ambition set out in the Conservative Party Manifesto and the Life Sciences Vision.Read the ABPI Open Letter to the Conservative Candidates
ABPI statement on biomarker testing
The ABPI commented in support of a call led by the Institute of Cancer Research (ICR) for all cancer patients to be offered genetic testing so they can get the best treatments available for them.
ABPI response to Life Sciences Competitiveness Indicators
The Government has today published Life Sciences Competitiveness Indicators, which provide data on the state of the life sciences sector in the UK.
ABPI welcomes first women's health strategy for England
The Government has today published the first women's health strategy for England, to tackle the gender health gap.
ABPI awarded PIF TICK trusted healthcare information creator status
The ABPI has been awarded ‘trusted health care information creator’ status by the Patient Information Forum, an accreditation known as the PIF TICK.
Latest blogs and events
The Innovative Medicines Fund - Good news for patients but has an opportunity been missed to be more ambitious?
NHS England and Improvement (NHSE/I) has announced the launch of the Innovative Medicines Fund. The ABPI’s Director of Value and Access Policy, Paul Catchpole, provides further commentary on the announcement.
Working together, we are all determined to create more medicines for pregnant women
Steve Hoare, the ABPI's Head of Safety and Quality, talks about how industry is trying to address the lack of medicines approved for pregnant women.
Worth the wait – The Goldacre review
Our thoughts on Professor Ben Goldacre’s “Better, broader, safer” report into health data.
Innovative medicines can bring hope to people with rare diseases – let’s get them to patients
England’s Action Plan for Rare Diseases contains important commitments to ensure that people with rare diseases get faster diagnosis, better care and timelier access to the treatments they desperately need.
Key content hubs
This covers the latest research from the ABPI-Ipsos attitudes towards pharmaceutical companies in the UK study.
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
Interesting report from @UKOnward today on how to make the UK a #ScienceSuperpower. The pharmaceutical industry invests more in UK R&D than any other sector and is critical to success. 🔽 https://t.co/Cwe6SFFacl— ABPI (@ABPI_UK) August 4, 2022
"The world has a once in a generation opportunity to transform how it deals with future pandemics."@ThomasCueni & @CEPIvaccines @DrRHatchett call global stakeholders to ensure poorer nations are better equipped before the next pandemic hits. @statnews https://t.co/dsvWoWpIol— IFPMA (@IFPMA) August 3, 2022